A Tunable T7 Expression Platform in Probiotic Escherichia coli Nissle 1917 with Application to Lysostaphin Production
This study establishes an optimized, tunable T7 expression platform in the probiotic *Escherichia coli* Nissle 1917 by balancing T7 RNA polymerase supply and promoter architecture, enabling efficient extracellular production of functional antimicrobial proteins like lysostaphin.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
In the vast, microscopic world of bacteria, scientists have long sought a way to turn simple cells into tiny factories capable of manufacturing medicines, enzymes, and other useful proteins. For decades, the workhorse of this industry has been a specific strain of E. coli known for its speed and ease of genetic manipulation. However, a different strain of E. coli, called Nissle 1917, offers a unique advantage: it is a probiotic, a "good" bacterium that has been safely used in humans for over a century to support gut health. This makes it an ideal candidate for a new kind of biotechnology, one where the bacteria themselves could travel inside the body to deliver drugs or fight infections directly at the site of a disease. To make this happen, researchers need a reliable switch to turn on the production of these therapeutic proteins. The most powerful switch available is a system derived from a virus that infects bacteria, known as the T7 system. This system uses a specialized enzyme, an RNA polymerase, to read genetic instructions and build proteins with incredible speed. The challenge has been figuring out how to install this viral switch into the probiotic bacteria without overwhelming them, a task that requires a delicate balance between power and control.
A team of researchers set out to solve this problem by building a custom expression platform inside the probiotic E. coli Nissle 1917. Their goal was to create a system that could produce functional proteins efficiently, specifically testing it with a protein called lysostaphin, which acts as a weapon against harmful staph bacteria. The first step in their process involved cleaning the genetic house of the probiotic bacteria. The natural strain carries two small, circular pieces of DNA called plasmids that are not essential for its survival but occupy space and resources. The researchers removed these native plasmids, creating a streamlined version of the bacteria. They found that this cleanup did not slow down the bacteria's growth, but it did make the cells more receptive to new genetic instructions, allowing them to produce more of the target proteins than the unmodified version.
With a cleaner host, the team turned their attention to the engine of the production system: the supply of the viral enzyme, T7 RNA polymerase. A common assumption in genetic engineering is that more of this enzyme means more protein production, so the researchers tested this idea by providing the bacteria with different amounts of the enzyme using various genetic tools. They created versions of the bacteria that carried the enzyme instructions on plasmids that existed in high, medium, and low numbers within the cell. Surprisingly, they discovered that flooding the cell with the enzyme did not lead to the best results. In fact, the version with the highest amount of the enzyme produced less of the final protein than the version with a moderate, low-copy supply. The most successful setup was one that provided a steady, balanced amount of the enzyme, suggesting that the bacteria have a limit to how much genetic activity they can handle before the system becomes inefficient.
To refine this balance further, the researchers tweaked the genetic switch that controls the enzyme's production. They altered a small gap in the DNA sequence that acts as a spacer, effectively changing how strongly the switch opens. By testing many different variations of this spacer, they identified a specific configuration that allowed the bacteria to produce the highest levels of a glowing green protein used as a marker. This optimized setup, which combined the cleaned-up bacteria with the balanced enzyme supply and the tuned switch, was then put to the test with the real target: lysostaphin. The results were significant. The engineered bacteria successfully produced and secreted the lysostaphin protein into their surrounding environment. The final yield reached an activity level of 540.94 units per milliliter and a protein concentration of 1.02 grams per liter. This demonstrated that the system was not just a theoretical success but a practical method for creating a functional antimicrobial protein.
The study also confirmed that this platform was versatile enough to handle other types of proteins, not just the glowing marker or the antimicrobial enzyme. The researchers successfully produced two other distinct proteins, one that helps the bacteria transport sugar and another that modifies sugar molecules, proving the system could work with different molecular shapes and functions. While the experiments were conducted in small laboratory flasks and the long-term stability of the genetic changes still needs to be tested in larger industrial settings, the findings provide a clear roadmap for using probiotic bacteria as production factories. The key takeaway is that in the world of synthetic biology, more is not always better; the most efficient production comes from finding the precise equilibrium where the host cell is supported, not overwhelmed, by the machinery it is asked to run. This approach opens the door for using safe, probiotic bacteria to manufacture complex medicines and therapeutic agents directly within the human body.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.